Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$83,258.00-2.72%ETH$2,567.87-4.78%GOLD$4,136.70-1.20%OIL$88.94-0.56%
Smart Investors Daily
SID Premium
Pfizer Inc. logo

NASDAQ · PFE

Pfizer Inc.

Healthcare · Drug Manufacturers - General

$27.50

Up+$0.50 (+1.82%)

Updated Oct 7, 2026, 9:20 PM

SID Score

7.0/10

Composite research score

Smart Money

65/100

Neutral

Market cap
146.75B
P/E ratio
14.94
Dividend yield
6.25%
52-week range
$23.62 – $29.21
Volume
24.09M
Avg. volume
68.83M

Price performance · PFE

PFE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

PFE closed at $27.50 after 21 trading sessions, down 1.04% for the selected period.

Last close
$27.50
Period change
-1.04%
Period low
$27.41
Period high
$28.72
Daily close
View OHLC price history
PFE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$27.48$27.71$27.20$27.5024.09M
Oct 5, 2026$27.65$27.72$27.12$27.4133.01M
Oct 2, 2026$28.145$28.16$27.44$27.8035.01M
Oct 1, 2026$28.445$28.585$28.075$28.1230.49M
Sep 30, 2026$28.79$28.945$28.52$28.5233.64M
Sep 29, 2026$28.60$28.76$28.26$28.7233.31M
Sep 28, 2026$28.62$28.87$28.39$28.7224.95M
Sep 25, 2026$28.45$28.69$28.17$28.6727.76M
Sep 24, 2026$28.20$28.85$28.20$28.4134.77M
Sep 23, 2026$27.96$28.23$27.84$28.1833.81M
Sep 22, 2026$27.74$28.00$27.49$27.9326.67M
Sep 21, 2026$27.65$27.92$27.53$27.7428.78M
Sep 18, 2026$27.64$27.66$27.34$27.6675.59M
Sep 17, 2026$27.62$27.81$27.55$27.6429.01M
Sep 16, 2026$27.64$27.69$27.36$27.4626.05M
Sep 15, 2026$27.615$27.66$27.245$27.5540.44M
Sep 14, 2026$28.08$28.19$27.685$27.7228.57M
Sep 11, 2026$27.80$27.85$27.42$27.7225.56M
Sep 10, 2026$27.69$27.75$27.40$27.6528.81M
Sep 9, 2026$27.76$27.975$27.57$27.7829.14M
Sep 8, 2026$28.015$28.145$27.715$27.7931.77M

Latest PFE news

The latest Smart Investors Daily articles mentioning PFE.

Stock researchCompany · Overview

PFE research

Overview

Company profile and research snapshot.

Company profile

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$30.00
Implied upside
—
Analysts
13
PFE recent ratings
DateFirmRatingTarget
Oct 6, 2026ScotiabankSector Outperform—
Sep 10, 2026HSBCHold—
Aug 7, 2026GuggenheimBuy—
Jul 13, 2026GuggenheimBuy—
Jul 13, 2026BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

3 AI Healthcare Stocks With Earnings Growth Up To 15%

Runaway demand for AI data centers, highlighted by Nvidia’s US$5.7t market cap milestone, shows how quickly capital is chasing tools that can crunch medical data, scan images, and support virtual care at global scale. That same engine is starting to reshape healthcare. Missing the early phase may mean missing where a lot of value could potentially accrue. This article breaks down three AI healthcare stocks from the screener that are worth watching. The three stocks covered below are only a...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By